Alamar Biosciences (NASDAQ:ALMR) Price Target Raised to $35.00

Alamar Biosciences (NASDAQ:ALMR) had its price target raised by JPMorgan Chase & Co. from $32.00 to $35.00 in a research note published on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other research analysts have also weighed in on ALMR. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Stifel Nicolaus upped their price target on Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday. Wall Street Zen raised Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. Zacks Research upgraded Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. Finally, Leerink Partners started coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They set an “outperform” rating and a $35.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $31.80.

Alamar Biosciences Price Performance

Alamar Biosciences stock opened at $32.92 on Tuesday. The business’s fifty day simple moving average is $25.37. The stock has a market capitalization of $2.28 billion and a price-to-earnings ratio of -18.92. Alamar Biosciences has a 52-week low of $18.84 and a 52-week high of $38.54.

Alamar Biosciences (NASDAQ:ALMR) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.14. The business had revenue of $29.43 million during the quarter. As a group, equities analysts expect that Alamar Biosciences will post -1.3 EPS for the current fiscal year.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.